CIBC Asset Management
CTKB icon

CIBC Asset Management’s Cytek Biosciences CTKB Stock Holding History

CIBC Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,100
Closed -$38.5K – 1378
2025
Q3 		$38.5K Hold
11,100
– – ﹤0.01% 1230
2025
Q2 		$37.7K Hold
11,100
– – ﹤0.01% 1208
2025
Q1 		$44.5K Sell
11,100
-311
-3% -$1.61K ﹤0.01% 1165
2024
Q4 		$74.1K Buy
11,411
+585
+5% +$3.48K ﹤0.01% 1192
2024
Q3 		$60K Buy
10,826
+466
+4% +$2.64K ﹤0.01% 1197
2024
Q2 		$57.8K Sell
10,360
-459
-4% -$2.76K ﹤0.01% 1128
2024
Q1 		$72.6K Hold
10,819
– – ﹤0.01% 1101
2023
Q4 		$98.7K Buy
+10,819
New +$68.1K ﹤0.01% 1055

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

CIBC Asset Management's CTKB Position: Q4 2025 in Review

CIBC Asset Management sold out of Cytek Biosciences (CTKB) in Q4 2025, closing a stake of 11,100 shares — an estimated $38.5K sold.

CIBC Asset Management first reported a position in CTKB in Q4 2023 and held it in 8 quarters. The position peaked at $98.7K in Q4 2023. 155 funds tracked by Wall St. Rank hold CTKB as of Q4 2025.

  • CIBC Asset Management reported no remaining Cytek Biosciences position as of Q4 2025 after selling out during the quarter.
  • CIBC Asset Management sold 11,100 Cytek Biosciences shares in Q4 2025, an estimated $38.5K.
  • CIBC Asset Management first reported a position in Cytek Biosciences in Q4 2023 and held it in 8 quarters.
  • CIBC Asset Management's Cytek Biosciences position peaked at $98.7K in Q4 2023.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2025.

Based on CIBC Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.